Turning Point Therapeutics, Inc.
TPTX · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $2 | $5 | $2 | $0 |
| - Cash | $0 | $1 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $4 | $1 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 23.3% | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 0% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -754.4% | -619.6% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -767.3% | -629.2% | – | – |
| EPS Diluted | -5.79 | -3.85 | -2.99 | -1.66 |
| % Growth | -50.4% | -28.8% | -80.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |